Who
Adrian Rawcliffe
Director
Company insider
Files Form 4 as: Director, Wave Life Sciences; Chief Executive Officer, Adaptimmune Therapeutics.
In numbers
- Trades disclosed
- 73
- Buys
- 0
- Sells
- 33
- Bought
- $0
- Sold
- $2.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 18 Jan 2016
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —10,700 at $0.00 | filing |
| 5 Oct 2026filed 7 Oct 2026 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $67K12,700 at $5.29 | filing |
| 12 Aug 2026filed 13 Aug 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $67K12,700 at $5.29 | filing |
| 8 Dec 2025filed 10 Dec 2025 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —42,000 at $0.00 | filing |
| 8 Dec 2025filed 10 Dec 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code M | $251K42,000 at $5.97 | filing |
| 8 Dec 2025filed 10 Dec 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $630K42,000 at $15.00 | filing |
| 13 Nov 2025filed 14 Nov 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $109K16,115 at $6.79 | filing |
| 11 Aug 2025filed 13 Aug 2025 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,200 at $0.00 | filing |
| 11 Aug 2025filed 13 Aug 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —12,700 at $0.00 | filing |
| 20 Feb 2025filed 20 Feb 2025 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —5,143,248 at $0.00 | filing |
| 20 Feb 2025filed 20 Feb 2025 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,428,832 at $0.00 | filing |
| 17 Jan 2025filed 17 Jan 2025 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $18K30,601 at $0.58 | filing |
| 15 Jan 2025filed 15 Jan 2025 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $17K29,096 at $0.57 | filing |
| 13 Jan 2025filed 15 Jan 2025 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $7,39812,539 at $0.59 | filing |
| 13 Jan 2025filed 15 Jan 2025 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $11K17,934 at $0.59 | filing |
| 12 Aug 2024filed 14 Aug 2024 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,230 at $0.00 | filing |
| 12 Aug 2024filed 14 Aug 2024 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —16,115 at $0.00 | filing |
| 17 Jan 2024filed 17 Jan 2024 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $20K30,080 at $0.67 | filing |
| 16 Jan 2024filed 17 Jan 2024 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $7,3509,304 at $0.79 | filing |
News
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026WVE · manilatimes.net · 20 Oct 2026Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026WVE · manilatimes.net · 19 Oct 2026WAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head ComparisonWVE · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Adrian Rawcliffe; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.